¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"blood group specific substance"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • age-specific fertility rate
    ¿¬·Éº°»ý½Ä·ü
  • age-specific rate
    ¿¬·Éº°ºñÀ²
  • cause-specific rate
    ¿øÀκ°ºñÀ²
  • donor-specific phage
    Á¦°øÀÚÆ¯ÀÌÆÄÁö, °ø¿©ÀÚÆ¯ÀÌÆÄÁö
  • granulocyte-specific antigen
    °ú¸³±¸Æ¯ÀÌÇ׿ø
  • neuron-specific enolase
    ´º·±Æ¯ÀÌ¿¡³î¶ó¾ÆÁ¦
  • organ specific antigen
    Àå±âƯÀÌÇ׿ø
  • platelet-specific antigen
    Ç÷¼ÒÆÇƯÀÌÇ׿ø
  • prostate specific antigen
    Àü¸³»ùƯÀÌÇ׿ø
  • species-specific
    Á¾Æ¯ÀÌ-
  • species-specific antigen
    Á¾Æ¯ÀÌÇ׿ø
  • species-specific reactivity
    Á¾Æ¯À̹ÝÀÀ¼º
  • specific
    1. ƯÀÌ-, ƯÁ¤- 2. Á¾-
  • specific absorption rate
    ºñÈí¼öÀ²
  • specific action
    ƯÀÌÀÛ¿ë
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • enteric group
    âÀÚ±Õ±º
  • evocative group therapy
    Ç¥ÇöÁý´Ü¿ä¹ý
  • functional group
    ÀÛ¿ë±â
  • group
    ¹«¸®, ±º, Áý´Ü
  • glucophore group
    ´ã´ç±â
  • green or yellow vegetable group
    ³ìȲ»öä¼Ò·ù
  • group hospital
    º´¿øÁ¶ÇÕ
  • group medicine
    Áý´ÜÁø·á, Çùµ¿Áø·á
  • group practice
    Áý´Ü°³¾÷
  • group psychotherapy
    Áý´ÜÁ¤½Å¿ä¹ý
  • group displacement law
    Áý´Üº¯À§¹ýÄ¢
  • group fascicular repair
    ½Å°æ¼¶À¯´Ù¹ß±ººÀÇÕ(¹ý)
  • group reference value
    Áý´Ü±âÁØÄ¡
  • haptenic group
    ºÒ¿ÏÀüÇ׿ø±º, ÇÕÅÙ±º
  • high risk group
    °íÀ§Çèµµ±º
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • released substance
    ¹æÃâ¹°Áú(Û¯õóÚªòõ).
  • renal pressor substance
    ½Å½Â¾Ð¹°Áú(ãìã°äâÚªòõ).
  • BAC (blood alcohol concentration)
    Ç÷Áß¾ËÄڿóóµµ
  • BOLD(blood oxygenation level dependant)
    Ç÷Áß »ê¼ÒÄ¡ ÀÇÁ¸
  • BP=£¾blood pressure
    Ç÷¾Ð.
  • BUN => blood urea nitrogen
    Ç÷Áß ¿ä¼Ò Áú¼Ò
  • BUN => blood urea nitrogen
    Ç÷Áß¿ä¼ÒÁú¼Ò
  • BUN=> blood urea nitrogen
    Ç÷¾× ¿ä¼Ò Áú¼Ò
  • BUN=£¾blood urea nitrogen
    Ç÷Áß¿ä¼ÒÁú¼Ò.
  • CBC =>complete blood count
    ÀüÇ÷±¸°è»ê(Ä¡)
  • ELBF=£¾effective liver blood flow
    À¯È¿¼º °£Ç÷·ù.
  • ELBF=£¾effective liver blood flow
    À¯È¿ °£Ç÷·ù.
  • Lutheran blood groups
    ·çÅ×¶õÇ÷¾×±º
  • Lutheran s blood groups
    ·çÅ×¶õÇ÷¾×±º.
  • MBP=£¾mean blood pressure
    Áß°£Ç÷¾Ð ¡ìÀÏÀÎÀÇ¡í, Æò±ÕÇ÷¾Ð.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • group of muscles
    ±ÙÀ°¹«¸®, ±Ù__ÐÉÏØ).
  • group practice
    Áý´Ü°³¾÷(̤ËÀ˧ ).
  • group psychotherapy
    Áý´ÜÁ¤½ÅÄ¡·á(ó¢Ó¥ïñãêö½Öû)(¿ä¹ý)
  • group reaction
    Áý´Ü¹ÝÀÀ(̤ËÀËÑËô).
  • group reference value
    Áý´Ü±âÁØ<--ÂüÁ¶>Ä¡
  • group test
    Áý´Ü½ÃÇè(ÊÙËàÌ´).
  • haptenic group
    ÇÕÅÙ±â(¡­Ðñ).
  • hearing aid, group
    Áý´Üº¸Ã»±â
  • high risk group
    °íÀ§Çèµµ±º(Ë­Ëô̴̬˴).
  • hydroxyl group
    ÇÏÀ̵å·Ï½Ç±â(¡­Ðñ).
  • incompatibility group, plasmid
    ÇÃ¶ó½º¹Ìµå ºñÀûÇÕ±º
  • indeterminate group
    ¹ÌÁ¤Çü±º(ËÑËøÌ´Ë´).
  • indeterminate group
    ¹ÌÁ¤Çü±º(Ú±ïÒúþÏØ).
  • labile methyl group
    ºÒ¾ÈÁ¤¸ÞÆ¿±â.
  • linkage group
    ¿¬¼â±º(ææáðÏØ).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • critical group
    ÀӰ豺(×üÍ£ÏØ)
  • diazo group
    µð¾ÆÁ¶ ±â(Ðñ)
  • diazonium group
    µð¾ÆÁ¶´½ ±â(Ðñ)
  • earthy group
    Å伺±â(÷ÏàõÐñ)
  • end-group analysis
    Á¾´Ü±â ºÐ¼® (ðûÓ®ÐñÝÂà°)
  • fatty acyl group
    Áö¹æ(ò·Û¸) ¾Æ½Ç±â(Ðñ)
  • fidelity group
    Á¤È®µµ ±â(ïáü¬ÓøÐñ)
  • formimino group
    Æ÷¸§À̹̳ë±â(Ðñ)
  • formyl group
    Æ÷¸£¹Ð±â(Ðñ)
  • functional group
    ÀÛ¿ë±â(íÂéÄÐñ)
  • functional group isomer
    ÀÛ¿ë±â(íÂéÄÐñ) À̼ºÃ¼(ì¶àõô÷)
  • glucosyl group
    ±Û·çÄڽDZâ(Ðñ)
  • glycoaldehyde group
    ±Û¶óÀÌÄھ˵¥ÇÏÀ̵å±â(Ðñ)
  • glycolaldehyde group
    ±Û¶óÀÌÄݾ˵¥ÇÏÀ̵å±â(Ðñ)
  • glycoloyl group
    ±Û¶óÀÌÄÚ·ÎÀϱâ(Ðñ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
ABC absolute basophil count; absolute bone conduction; acalculous biliary colic; acid balance control; a...
BlT bleeding time; blood test; blood type, blood typing
CBL circulating blood lymphocytes; chronic blood loss; cord blood leukocytes
DRBC denaturated red blood cell; dog red blood cell; donkey red blood cell
EHBF estimated hepatic blood flow; exercise hyperemia blood flow; extrahepatic blood flow
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
DLIS Digoxin-like immunoreactive substance
EDLS Endogenous digitalis-like substance
HSS Hepatic Stimulatory Substance
I-SP Immunoreactive substance P
ir SP Immunoreactive substance P
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • slow-reating substance
    Áö¹ÝÀÀ¼º ¹°Áú
    ¾î¶² ÆòȰ±ÙÀÇ ´À¸®°í Áö¼Ó¼ºÀÎ ¼öÃàÀ» ÀÏÀ¸Å°´Â ¾Æ³ªÇʶô½Ã ¹ÝÀÀ ½Ã¿¡ ¹æÃâµÇ´Â ¹°Áú ±âÈ£ SRS-A.
  • substance defect
    ¹°Áú °áÇÌ
  • substance P fiber
    P ¹°Áú ¼¶À¯
  • toxic substance
    À¯µ¶ ¼ººÐ, µ¶¹°
  • transmitter substance
    Àü´Þ ¹°Áú
  • white substance
    ¹é»ö Áú
  • arterial blood gas
    µ¿¸ÆÇ÷ °¡½º ºÐ¾Ð
  • arterial blood gas study
    µ¿¸ÆÇ÷ °³½º ºÐ¾Ð ÃøÁ¤
  • artificial blood vessel
    Àΰø Ç÷°ü
  • autoimmune blood dyscrasia
    ÀÚ°¡ ¸é¿ª¼º Ç÷¾× ÀÌ»ó
  • autologous blood recovery system
    ÀÚ°¡ Ç÷¾× ȸº¹ ÀåÄ¡
  • automated noninvasive blood pressure device
    ºñħ½ÀÀû ÀÚµ¿ Ç÷¾Ð±â
  • basal blood pressure
    ±âÀú Ç÷¾Ð
  • black blood imaging
    ÈæÇ÷·ù ¿µ»ó
  • blood
    ÇÇ, Ç÷¾×
    1. ¸Æ°ü°è¸¦ È帣°í ÀÖ´Â ¾×ü·Î ¼¼Æ÷ ¼ººÐÀÎ Ç÷±¸¿Í Ç÷ûÀ¸·Î ±¸¼ºµÈ´Ù. ½ÉÀå ¹× Ç÷°ü Áï ¼øÈ¯°è¸¦ ä¿ì°í ÀÖ´Â ¾×üÀÌ´Ù. 2. ÇÇ, ½ÉÀå, µ¿¸Æ, ¸ð¼¼Ç÷°ü ¹× Á¤¸Æ³»¸¦ ¼øÈ¯Çϸ鼭 ½Åü³» ¼¼Æ÷¿¡ ¿µ¾çºÐ°ú »ê¼Ò¸¦ ¿î¹ÝÇÏ´Â ¾×üÀ̸ç, ÀûÇ÷±¸, ¹éÇ÷±¸, Ç÷¼ÒÆÇ µîÀ» Æ÷ÇÔÇÑ À¯Çü ¼ººÐ°ú Ç÷ÀåÀ¸·Î ±¸¼ºµÇ¾î ÀÖ´Ù. 3. ²öÀû²öÀûÇÑ ¾×ü·Î¼­, ÀûÇ÷±¸ÀÇ Ç÷»ö¼Ò ?¹®¿¡ ¼±È«»öÀ» ¶è´Ù. 4. Ç÷°ü ¼ÓÀ» È帣°í ÀÖ´Â ¾×»óÀÇ Á¶Á÷. ¼±¸íÇÑ Àû»öÀ» ¶ì°í ÀÖ°í ºÒÅõ¸íÇÏ¸ç ±ÕÀÏÇÏ°Ô º¸ÀδÙ. ±×·¯³ª Ç÷¾×ÀÇ ÀÛÀº ¹æ¿ïÀ» À¯¸®ÆÇ¿¡ ¾ã°Ô Æì°í Çö¹Ì°æÀ¸·Î º¸¸é Åõ¸íÇÑ ¾×ü ¼Ó¿¡ Ç÷±¸°¡ ºÎÀ¯Çϰí ÀÖ¾î ±ÕÀÏÇÏÁö ¾ÊÀ½À» ¾Ë ¼ö ÀÖ´Ù. Ç÷¾×ÀÇ ÁÖµÈ ¿ªÇÒÀº °¢Á¾ ¹°ÁúÀÇ ¿î¹ÝÀ̸ç, Æó¿¡¼­ ¼·ÃëÇÑ »ê¼Ò³ª ¼ÒÈ­°ü¿¡¼­ Èí¼öÇÑ ¿µ¾ç¼Ò µîÀ» Àü½ÅÀÇ ¸ðµç ¼¼Æ÷·Î º¸³»°í ¹Ý´ë·Î ¼¼Æ÷¿¡¼­ ¸¸µé¾îÁø ź»ê°¡½º³ª ³ëÆó¹°À» ¿î¹ÝÇØ¼­ Æó, ½ÅÀå, ÇǺΠµîÀ» ÅëÇØ¼­ ¸ö¹ÛÀ¸·Î ¹è¼³ÇÑ´Ù. ¶Ç °ñ°Ý±ÙÀ̳ª °£°ú °°ÀÌ ¿­ »ý»êÀÌ ¿Õ¼ºÇÑ °÷À¸·ÎºÎÅÍ ´Ù¸¥ ºÎºÐÀ¸·Î ¿­À» ¿Å°Ü¼­ ü¿­ÀÇ ºÐÆ÷¸¦ ±ÕµîÇÏ°Ô Çϰí, ÇǺο¡¼­ ¹æ¿­ÇÏ¿© ü¿ÂÀ» ÀÏÁ¤ÇÏ°Ô À¯Áö½ÃŰ´Â µ¥µµ °ü¿©ÇÑ´Ù. Ç÷¾×·®Àº üÁßÀÇ ¾à 8 %, ºñÁßÀº 1.06À̹ǷΠüÁßÀÌ 60 kgÀÎ ¶§ ¾à 4.5§¤°¡ µÈ´Ù. Ç÷¾×·®Àº °ÅÀÇ ÀÏÁ¤Çؼ­ ¾×ü¸¦ ¼·ÃëÇßÀ» ¶§³ª ÀûÀº ¾çÀÇ ÃâÇ÷ÀÌ ÀÖÀ» ¶§µµ Ç÷°ü ¼ÓÀÇ ¼øÈ¯ Ç÷¾×·®À» ÀÚÀ²ÀûÀ¸·Î Á¶ÀýÇÏ¿© Àüü Ç÷¾×·®Àº º¯ÇÏÁö ¾Ê´Â´Ù. ÇÑÆí, ´ë·®ÀÇ ¹°À» ¸¶¼ÌÀ» ¶§ ¼öºÐÀº °ð Ç÷¾×¿¡¼­ Á¶Á÷À¸·Î ³ª°¡°Å³ª ½ÅÀåÀ¸·ÎºÎÅÍ ¹è¼³µÈ´Ù. Ç÷¾×ÀÇ Á¡Á¶µµ´Â ¹°ÀÇ ¾à 5¹èÀ̰í, ÁÖ·Î Ç÷±¸ ¼ö¿¡ µû¶ó º¯ÇÑ´Ù. ºóÇ÷ÀÏ ¶§Ã³·³ ÀûÇ÷±¸°¡ °¨¼ÒÇϸé Á¡Á¶µµ°¡ ³·¾ÆÁ®¼­ Ç÷¾×ÀÌ Ç÷°ü ³»¸¦ È带 ¶§ ÀúÇ×ÀÌ °¨¼ÒµÇ¹Ç·Î Ç÷¾ÐÀÌ ¶³¾îÁø´Ù. µû¶ó¼­ Ç÷¾×ÀÇ Á¡Á¶µµ°¡ Ç÷¾ÐÀ» À¯ÁöÇÏ´Â µ¥¿¡ Áß¿äÇÑ ±¸½ÇÀ» Çϰí ÀÖÀ½À» ¾Ë ¼ö ÀÖ´Ù. Ç÷¾×ÀÇ »ïÅõ¾ÐÀº 6.7±â¾ÐÀ¸·Î 0.9 %ÀÇ ½Ä¿°¼ö¿Í °°´Ù. ¸¸¾à Ç÷¾×º¸´Ù ³·Àº »ïÅõ¾ÐÀÇ ½Ä¿°¼ö¿¡ Ç÷¾×À» ³ÖÀ¸¸é Ç÷±¸ ¼Ó¿¡ ¼öºÐÀÌ »¡·Á µé¾î°¡ ºÎÇ®¾î ¸¶Ä§³»´Â ÆÄ±«µÈ´Ù. À̰ÍÀ» ¿ëÇ÷À̶ó°í ÇÑ´Ù. ¶Ç ¹Ý´ë·Î Ç÷¾×º¸´Ù ³ôÀº »ïÅõ¾ÐÀÇ ½Ä¿°¼ö ¾È¿¡¼­´Â Ç÷±¸ ¼ÓÀÇ ¼öºÐÀÌ ¹ÛÀ¸·Î ³ª¿Í Ç÷±¸´Â ¿À±×¶óµé°í ¸¸´Ù. ±×¸®°í Ç÷¾×°ú °°Àº »ïÅõ¾ÐÀÇ ½Ä¿°¼ö¸¦ »ý¸®Àû ½Ä¿°¼ö¶ó ÇÑ´Ù. Ç÷¾×ÀÇ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
substance abuse treatment centres Health facilities providing therapy and/or rehabilitation for substance-dependent individuals. Methadone distribution centres are included.
(12 Dec 1998)
substance dependence A pattern of behavioural, physiologic, and cognitive symptoms that develop due to substance use or abuse; usually indicated by tolerance to the effects of the substance and withdrawal symptoms that develop when use of the substance is terminated.
(05 Mar 2000)
substance-induced organic mental disorders Mental disorders caused by use of drugs, e.g., cocaine.
(05 Mar 2000)
substance of lens of eye That which constitutes the lens of the eye, composed of a nucleus and a cortex and covered by an epithelium.
Synonym: substantia lentis.
(05 Mar 2000)
substance P A vasoactive intestinal peptide (1348 D) found in the brain, spinal ganglia and intestine of vertebrates. Induces vasodilatation, salivation and increases capillary permeability. Sequence: RPKPQFFGLM.
(18 Nov 1997)
substance-related disorders These non-psychotic disorders include those related to the taking of a drug of abuse (including alcohol), to the side effects of a medication, and to toxin exposure.
(12 Dec 1998)
substance withdrawal syndrome <syndrome> Physiological and psychological symptoms associated with withdrawal from the use of a drug after prolonged administration or habituation. The concept includes withdrawal from smoking or drinking, as well as withdrawal from an administered drug.
(12 Dec 1998)
innominate substance The region of the forebrain that lies ventral to the anterior half or so of the lentiform nucleus, extending in the frontal plane from the lateral preopticohypothalamic zone laterally over the optic tract to the amygdala (amygdaloid body); rostrally it tapers off over the dorsal border of the olfactory tubercle, caudally it ends where the internal capsule reaches the surface to form the cerebral peduncle or pes pedunculi. Notable among its polymorphic cell population is the large-celled basal nucleus of Meynert. These magnocellular elements within the substantia i. Are present in the medial septum and the diagonal band of Broca, but occur in largest numbers ventral to the globus pallidus. Histochemical evidence indicates that magnocellular elements distribute cholinergic fibres widely in the cerebral cortex and that these cells undergo selective degeneration in Alzheimer's disease.
Synonym: substantia innominata.
(05 Mar 2000)
interspongioplastic substance An obsolete term for cytochylema.
(05 Mar 2000)
threshold substance Any material (e.g., glucose) that is excreted in the urine only when its plasma concentration exceeds a certain value, termed its threshold.
Synonym: threshold body.
(05 Mar 2000)
tigroid substance The material consisting of granular endoplasmic reticulum and ribosomes that occurs in nerve cell bodies and dendrites.
Synonym: basophil substance, basophilic substance, chromophil substance, Nissl bodies, Nissl granules, substantia basophilia, tigroid bodies, tigroid substance.
(05 Mar 2000)
ergastic substance Metabolically inert products of photosynthesis, such as starch grains and fat globules.
(18 Nov 1997)
exophthalmos-producing substance A factor found in crude extract of pituitary tissue that produced exophthalmos in laboratory animals (especially fish). Its existence and role in producing exophthalmopathy in Graves' disease is questioned.
(05 Mar 2000)
Kendall's substance A group of corticosteroids. Kendall's compound A (11-dehydrocorticosterone); Kendall's compound B (corticosterone); Kendall's compound E (cortisone); Kendall's compound F (cortisol).
Synonym: Kendall's substance.
(05 Mar 2000)
united states substance abuse and mental health services administration An agency of the public health service concerned with the overall planning, promoting, and administering of programs pertaining to substance abuse and mental health. It is commonly referred to by the acronym samhsa. On 1 october 1992, the united states alcohol, drug abuse, and mental health administration (adamha) became samhsa. (telephone communication with samhsa 7 april 1992)
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • interested group
    (»çȸ)ÀÌÀͰøµ¿Ã¼;°øÅëÀÌÇØ´Üü(±¹°¡ Á¤´çŬ·´µî)
  • minority group
    ¼Ò¼ö¹ÎÁ·(Çѳª¶óÀÇ)
  • peer group
    µ¿·á Áý´Ü;µ¿¹è Áý´Ü
  • pressure group
    ¾Ð·Â ´Üü
  • primary group
    Á¦ ÀÏÂ÷ Áý´Ü(°¡Á¤,Ä£±¸ µî)
  • rape group
    ÅäÀÇ(Åä·Ð)±×·ì
  • reference group
    ÁذŠÁý´Ü(°³ÀÎÀÌ ÀÚ±â ŵµ.ÆÇ´ÜÀÇ ±âÁØÀ¸·Î ¿©±â´Â ƯÁ¤ Áý´Ü)
  • splinter group
    ºÐÆÄ;¼Ò¼öÆÄ
  • tail group
    TAIL UNIT
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
ÅëÇÕ°Ë»ö ¿Ï·á